FDA grants AMXT 1501 orphan drug status for malignant gliomas

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMXT 1501 to treat malignant gliomas, including a particularly aggressive childhood brain tumor called diffuse intrinsic pontine glioma (DIPG).

Read more: https://rarecancernews.com/news/fda-grants-amxt-1501-orphan-drug-status-malignant-gliomas/